Therapeutic Radiopharmaceuticals Labelled with New Emerging Radionuclides (67Cu, 186Re, 47Sc)
Closed for Proposals
Project Type
Coordinated Research ProjectProject Code
F22053
CRP
2073
Approved Date
03.09.2015Project Status
ClosedStart Date
18.03.2016Expected End Date
17.03.2020Completed Date
05.08.2020Description
This Coordinated Research Project (CRP) will identify important technical issues related to the production and quality control of emerging new radionuclides for use in the development of therapeutic radiopharmaceuticals. 67Cu, 186Re and 47Sc radionuclides have been selected based on their theranostic potential and their dual production routes through reactors and cyclotrons, target availability, and high specific activity production. Based on potential demand of member states a collaborated research is needed for the establishment of standardized production, quality control and other important issues including preparation of technical protocols and guidelines for ultimate radiopharmaceutical development. The CRP is focused on production methods of the 67Cu, 186Re and 47Sc radioisotopes as Theranostic Radionuclides for possible radiopharmaceutical development as well as research purposes.The objectives for this CRP are to:Formulate guidelines to enhance and strengthen the expertise and capability of Member States in deploying emerging 67Cu, 186Re and 47Sc therapeutic radioisotopes with “Theranostic” properties from research reactors and accelerators for medical applications in order to meet MS needs as well as to assimilate new developments and research initiatives.
Objectives
Formulate guidelines to enhance and strengthen the expertise and capability of Member States in deploying emerging 67Cu, 186Re and 47Sc therapeutic radioisotopes with “Theranostic” properties from research reactors and accelerators for medical applications in order to meet national needs as well as to assimilate new developments.
Specific Objectives
Development of preliminary procedures for preparation of potential Radiopharmaceuticals of interest based on the mentioned radioisotopes and preclinical studies.
Production of 67Cu, 186Re and 47Sc radionuclides using research reactors and accelerators for some participants for research and clinical use.
Development of target recovery procedures for the future productions based on the production methods under unified bench-marking to optimize the production expenses;
Development of quality control procedures for the produced radionuclides based on the production methods under unified bench-marking at the CRP group.
Development of targetry procedures for the radionuclide production based on the production methods under unified bench-marking at the CRP group.
Impact
The participants have enabled highly collaborative efforts which leverages the expertise offered by each of the participants. For example: CRP participants from Australia, Egypt, India, Iran and Poland have significant experience with isotope production with reactors, CRP participants from France, Hungary, Iran, Italy and Malaysia have expertise related to cross section measurements and/or theoretical modelling, CRP participants from Korea, Iran, Poland, Syria and USA have expertise related to target preparation (including recycling), CRP participants from Egypt, France, Japan, India, Iran, Italy, Syria, Poland and USA have expertise related to isotope purification techniques and CRP participants from Egypt, India, Poland, Saudi Arabia and USA have experience in peptide chemistry and radiolabelling.
The technical impacts of CRP are:
? Explore efficient production methods of 67Cu, 186Re and 47Sc radionuclides using research reactors and in accelerators for research and clinical use.
? Development of targetry procedures for the radionuclide production
? Development of quality control procedures based on the production methods
? Development of target recovery procedures based on the production methods
? Development of preliminary procedures for preparation of potential radiopharmaceuticals based on the radioisotopes of interest and preclinical studies.
Relevance
The CRP was involved the development of standardized production, quality control and recovery procedures for new emerging beta emitter “Theranostic” radionuclides (67Cu, 186Re and 47Sc) for ultimate use in radiopharmaceutical development.
CRP Publications
Poland
Proceedings
2018
I.Cieszykowska, D. Pawlak, W. Wojdowska, T. Janiak, M. Zoltowska, T. Barcikowski, J.L. Parus, R. Mikolajczak. Production of medical Sc radioisotopes: 44Sc and 47Sc. 17-th Workshop on Targetry and Target Chemistry. 27-31 August 2018, Coimbra, Portugal.